Top

Published in:

01-12-2020 | Influenza | Research

Identification of cellular microRNA miR-188-3p with broad-spectrum anti-influenza A virus activity

Authors: Huan Cui, Chunmao Zhang, Zongzheng Zhao, Cheng Zhang, Yingying Fu, Jiaming Li, Guanxi Chen, Mengxi Lai, Zhixiang Li, Shishan Dong, Ligong Chen, Zhaoyang Li, Chengyu Wang, Juxiang Liu, Yuwei Gao, Zhendong Guo

Published in: Virology Journal | Issue 1/2020

Abstract

Background

Influenza A virus (IAV) continues to pose serious threats to public health. The current prophylaxis and therapeutic interventions for IAV requires frequent changes due to the continuous antigenic drift and antigenic shift of IAV. Emerging evidence indicates that the host microRNAs (miRNAs) play critical roles in intricate host-pathogen interaction networks. Cellular miRNAs may directly target virus to inhibit its infection and be developed as potential anti-virus drugs.

Methods

In this study, we established a broad-spectrum anti-IAV miRNA screening method using miRanda software. The screened miRNAs were further verified by luciferase assay, viral protein expression assay and virus replication assay.

Results

Five cellular miRNAs (miR-188-3p, miR-345-5p, miR-3183, miR-15-3p and miR-769-3p), targeting 99.96, 95.31, 92.9, 94.58 and 97.24% of human IAV strains recorded in NCBI, respectively, were chosen for further experimental verification. Finally, we found that miR-188-3p downregulated PB2 expression at both mRNA and protein levels by directly targeted the predicted sites on PB2 and effectively inhibited the replication of IAV (H1N1, H5N6 and H7N9) in A549 cells.

Conclusions

This is the first report screening cellular miRNAs that broad-spectrum inhibiting IAV infection. These findings suggested that cellular miR-188-3p could be used for RNAi-mediated anti-IAV therapeutic strategies.

Available only for authorised users

Palese P, Shaw ML. Orthomyxoviridae: the viruses and their replication. In: Knipe DM, Howley PM, editors. Fields virology. 5th ed. Philadelphia: Lippincott Williams & Wilkins; 2007. p. 1647–89.

Taubenberger JK, Morens DM. 1918 influenza: the mother of all pandemics. Rev Biomed. 2006;17(1):69–79.CrossRef

Shrestha SS, Swerdlow DL, Borse RH, Prabhu VS, Finelli L, Atkins CY, et al. Estimating the burden of 2009 pandemic influenza A (H1N1) in the United States (April 2009–April 2010). Clin Infect Dis. 2011;52(suppl_1):S75–82.PubMedCrossRef

Liu J, Xiao H, Wu Y, Liu D, Qi X, Shi Y, et al. H7N9: a low pathogenic avian influenza A virus infecting humans. Curr Opin Virol. 2014;5:91–7.PubMedCrossRefPubMedCentral

Cox NJ, Subbarao K. Global epidemiology of influenza: past and present. Annu Rev Med. 2000;51(1):407–21.PubMedCrossRef

Johnson NP, Mueller J. Updating the accounts: global mortality of the 1918-1920 “Spanish” influenza pandemic. Bull Hist Med. 2002;76(1):105–15.PubMedCrossRef

Dawood FS, Iuliano AD, Reed C, Meltzer MI, Shay DK, Cheng PY, et al. Estimated global mortality associated with the first 12 months of 2009 pandemic influenza A H1N1 virus circulation: a modelling study. Lancet Infect Dis. 2012;12(9):687–95.PubMedCrossRef

Li C, Chen H. Enhancement of influenza virus transmission by gene reassortment. In: Influenza pathogenesis and control-volume I. Cham: Springer; 2014. p. 185–204.CrossRef

Yang ZF, Mok CK, Peiris JS, Zhong NS. Human infection with a novel avian influenza A (H5N6) virus. N Engl J Med. 2015;373(5):487–9.PubMedCrossRef

10.

Gao R, Cao B, Hu Y, Feng Z, Wang D, Hu W, et al. Human infection with a novel avian-origin influenza A (H7N9) virus. N Engl J Med. 2013;368(20):1888–97.PubMedCrossRef

11.

Loregian A, Mercorelli B, Nannetti G, Compagnin C, Palù G. Antiviral strategies against influenza virus: towards new therapeutic approaches. Cell Mol Life Sci. 2014;71(19):3659–83.PubMedCrossRef

12.

Hay AJ, Hayden FG. Oseltamivir resistance during treatment of H7N9 infection. Lancet. 2013;381(9885):2230–2.PubMedCrossRef

13.

Samson M, Pizzorno A, Abed Y, Boivin G. Influenza virus resistance to neuraminidase inhibitors. Antivir Res. 2013;98(2):174–85.PubMedCrossRef

14.

Wang J, Li F, Ma C. Recent progress in designing inhibitors that target the drug-resistant M2 proton channels from the influenza A viruses. Pept Sci. 2015;104(4):291–309.CrossRef

15.

Wienholds E, Plasterk RH. MicroRNA function in animal development. FEBS Lett. 2005;579(26):5911–22.PubMedCrossRef

16.

Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell. 2004;116(2):281–97.PubMedCrossRef

17.

Bhattacharyya SN, Habermacher R, Martine U, Closs EI, Filipowicz W. Relief of microRNA-mediated translational repression in human cells subjected to stress. Cell. 2006;125(6):1111–24.PubMedCrossRef

18.

Cheng AM, Byrom MW, Shelton J, Ford LP. Antisense inhibition of human miRNAs and indications for an involvement of miRNA in cell growth and apoptosis. Nucleic Acids Res. 2005;33(4):1290–7.PubMedPubMedCentralCrossRef

19.

Croce CM, Calin GA. miRNAs, cancer, and stem cell division. Cell. 2005;122(1):6–7.PubMedCrossRef

20.

Ma L, Teruya-Feldstein J, Weinberg RA. Tumour invasion and metastasis initiated by microRNA-10b in breast cancer. Nature. 2007;449(7163):682–8.PubMedCrossRef

21.

Tavazoie SF, Alarcón C, Oskarsson T, Padua D, Wang Q, Bos PD, et al. Endogenous human microRNAs that suppress breast cancer metastasis. Nature. 2008;451(7175):147–52.PubMedPubMedCentralCrossRef

22.

Hwang HW, Mendell JT. MicroRNAs in cell proliferation, cell death, and tumorigenesis. Br J Cancer. 2006;94(6):776–80.PubMedPubMedCentralCrossRef

23.

Scaria V, Hariharan M, Maiti S, Pillai B, Brahmachari SK. Host-virus interaction: a new role for microRNAs. Retrovirology. 2006;3(1):68.PubMedPubMedCentralCrossRef

24.

Lecellier CH, Dunoyer P, Arar K, Lehmann-Che J, Eyquem S, Himber C, et al. A cellular microRNA mediates antiviral defense in human cells. Science. 2005;308(5721):557–60.PubMedCrossRef

25.

Huang J, Wang F, Argyris E, Chen K, Liang Z, Tian H, et al. Cellular microRNAs contribute to HIV-1 latency in resting primary CD4+ T lymphocytes. Nat Med. 2007;13(10):1241.PubMedCrossRef

26.

Song L, Liu H, Gao S, Jiang W, Huang W. Cellular microRNAs inhibit replication of the H1N1 influenza A virus in infected cells. J Virol. 2010;84(17):8849–60.PubMedPubMedCentralCrossRef

27.

Ma YJ, Yang J, Fan XL, Zhao HB, Hu W, Li ZP, et al. Cellular micro RNA let-7c inhibits M1 protein expression of the H1N1 influenza A virus in infected human lung epithelial cells. J Cell Mol Med. 2012;16(10):2539–46.PubMedPubMedCentralCrossRef

28.

Zhang S, Wang R, Su H, Wang B, Sizhu S, Lei Z, et al. Sus scrofa miR-204 and miR-4331 negatively regulate swine H1N1/2009 influenza a virus replication by targeting viral HA and NS, respectively. Int J Mol Sci. 2017;18(4):749.PubMedCentralCrossRef

29.

Peng S, Wang J, Wei S, Li C, Zhou K, Hu J, et al. Endogenous cellular MicroRNAs mediate antiviral defense against influenza a virus. Mol Ther Nucleic Acids. 2018;10:361–75.PubMedCrossRef

30.

Jopling CL, Yi M, Lancaster AM, Lemon SM, Sarnow P. Modulation of hepatitis C virus RNA abundance by a liver-specific MicroRNA. Science. 2005;309(5740):1577–81.PubMedCrossRef

31.

Lanford RE, Hildebrandt-Eriksen ES, Petri A, Persson R, Lindow M, Munk ME, et al. Therapeutic silencing of microRNA-122 in primates with chronic hepatitis C virus infection. Science. 2010;327(5962):198–201.PubMedCrossRef

32.

Enright AJ, John B, Gaul U, Tuschl T, Sander C, Marks DS. MicroRNA targets in drosophila. Genome Biol. 2003;5(1):R1.PubMedPubMedCentralCrossRef

33.

John B, Enright AJ, Aravin A, Tuschl T, Sander C, Marks DS. Human microRNA targets. PLoS Biol. 2005;3(7):e264.PubMedCentralCrossRef

34.

Sun Q, Zhang Y, Yang G, Chen X, Zhang Y, Cao G, et al. Transforming growth factor-β-regulated miR-24 promotes skeletal muscle differentiation. Nucleic Acids Res. 2008;36(8):2690–9.PubMedPubMedCentralCrossRef

35.

Zhao Z, Guo Z, Zhang C, Liu L, Chen L, Zhang C, et al. Avian influenza H5N6 viruses exhibit differing pathogenicities and transmissibilities in mammals. Sci Rep. 2017;7(1):16280.PubMedPubMedCentralCrossRef

36.

Neuzil KM, Ortiz JR. Influenza vaccines and vaccination strategies. In: The vaccine book: Academic Press, Salt Lake City; 2016. p. 423–44.

37.

Keshavarz M, Dianat-Moghadam H, Sofiani VH, Karimzadeh M, Zargar M, Moghoofei M, et al. miRNA-based strategy for modulation of influenza A virus infection. Epigenomics. 2018;10(6):829–44.PubMedCrossRef

38.

Shi Y, Wu Y, Zhang W, Qi J, Gao GF. Enabling the ‘host jump’: structural determinants of receptor-binding specificity in influenza A viruses. Nat Rev Microbiol. 2014;12(12):822.PubMedCrossRef

39.

Albo C, Valencia A, Portela A. Identification of an RNA binding region within the N-terminal third of the influenza A virus nucleoprotein. J Virol. 1995;69(6):3799–806.PubMedPubMedCentralCrossRef

40.

Boulo S, Akarsu H, Ruigrok RW, Baudin F. Nuclear traffic of influenza virus proteins and ribonucleoprotein complexes. Virus Res. 2007;124(1–2):12–21.PubMedCrossRef

41.

Chen Y, Liang W, Yang S, Wu N, Gao H, Sheng J, et al. Human infections with the emerging avian influenza A H7N9 virus from wet market poultry: clinical analysis and characterisation of viral genome. Lancet. 2013;381(9881):1916–25.PubMedCrossRefPubMedCentral

42.

Chen H, Yuan H, Gao R, Zhang J, Wang D, Xiong Y, et al. Clinical and epidemiological characteristics of a fatal case of avian influenza A H10N8 virus infection: a descriptive study. Lancet. 2014;383(9918):714–21.PubMedCrossRef

43.

Peiris M, Yuen KY, Leung CW, Chan KH, Ip PLS, Lai RWM, et al. Human infection with influenza H9N2. Lancet. 1999;354(9182):916–7.PubMedCrossRef

44.

Fouchier RA, Schneeberger PM, Rozendaal FW, Broekman JM, Kemink SA, Munster V, et al. Avian influenza A virus (H7N7) associated with human conjunctivitis and a fatal case of acute respiratory distress syndrome. Proc Natl Acad Sci. 2004;101(5):1356–61.PubMedCrossRefPubMedCentral

45.

De Jong MD, Simmons CP, Thanh TT, Hien VM, Smith GJ, Chau TNB, et al. Fatal outcome of human influenza A (H5N1) is associated with high viral load and hypercytokinemia. Nat Med. 2006;12(10):1203.PubMedPubMedCentralCrossRef

46.

Xu F, Liu G, Liu Q, Zhou Y. RNA interference of influenza A virus replication by microRNA-adapted lentiviral loop short hairpin RNA. J Gen Virol. 2015;96(10):2971–81.PubMedCrossRef

47.

Herrera-Carrillo E, Liu YP, Berkhout B. Improving miRNA delivery by optimizing miRNA expression cassettes in diverse virus vectors. Hum Gene Ther Methods. 2017;28(4):177–90.PubMedPubMedCentralCrossRef

48.

Brown RAM, Richardson KL, Kalinowski FC, et al. Evaluation of microRNA delivery in vivo. Methods Mol Biol. 2018;1699:155–78.PubMedCrossRef

49.

Wu W, Hu Q, Wang W, Shao S, Zhao X, Bai H, et al. A PEGylated megamer-based microRNA delivery system activatable by stepwise microenvironment stimulation. Chem Commun (Camb). 2019;55(63):9363–6.CrossRef

50.

Zhang XF, Yang Y, Yang XY, Tong Q. MiR-188-3p upregulation results in the inhibition of macrophage proinflammatory activities and atherosclerosis in ApoE-deficient mice. Thromb Res. 2018;171:55–61.PubMedCrossRef

51.

Pei J, Zhang J, Yang X, Wu Z, Sun C, Wang Z, et al. TMED3 promotes cell proliferation and motility in breast cancer and is negatively modulated by miR-188-3p. Cancer Cell Int. 2019;19(1):75.PubMedPubMedCentralCrossRef

52.

Pichler M, Stiegelbauer V, Vychytilova-Faltejskova P, Ivan C, Ling H, Winter E, et al. Genome-wide miRNA analysis identifies miR-188-3p as a novel prognostic marker and molecular factor involved in colorectal carcinogenesis. Clin Cancer Res. 2017;23(5):1323–33.PubMedCrossRef

Title: Identification of cellular microRNA miR-188-3p with broad-spectrum anti-influenza A virus activity
Authors: Huan Cui
Chunmao Zhang
Zongzheng Zhao
Cheng Zhang
Yingying Fu
Jiaming Li
Guanxi Chen
Mengxi Lai
Zhixiang Li
Shishan Dong
Ligong Chen
Zhaoyang Li
Chengyu Wang
Juxiang Liu
Yuwei Gao
Zhendong Guo
Publication date: 01-12-2020
Publisher: BioMed Central
Keyword: Influenza
Published in: Virology Journal / Issue 1/2020
Electronic ISSN: 1743-422X
DOI: https://doi.org/10.1186/s12985-020-1283-9

ACC 2024 Congress Coverage

Heart Failure Video

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Identification of cellular microRNA miR-188-3p with broad-spectrum anti-influenza A virus activity

Abstract

Background

Methods

Results

Conclusions

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2020

Pulmonary endothelium-derived PD-L1 induced by the H9N2 avian influenza virus inhibits the immune response of T cells

Performance of commercially available anti-HDV enzyme-linked immunosorbent assays in Taiwan

Viral metagenomic analysis of chickens with runting-stunting syndrome in the Republic of Korea

Whole genome sequencing and genetic variations in several dengue virus type 1 strains from unusual dengue epidemic of 2017 in Vietnam

Detection of low-level HCV variants in DAA treated patients: comparison amongst three different NGS data analysis protocols

Reduction of Salmonella contamination on the surface of chicken skin using bacteriophage

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page